Dr G. Paul Amminger is Associate Professor at Orygen Youth Health Research Centre, Melbourne. His research spans from traditional high-risk research in schizophrenia to pioneering intervention studies during the onset phase of psychosis and recently in youth depression. He successfully tested the efficacy of omega-3 fatty acids in children with autism and in young people at ultra-high risk for psychosis. The publication of the study “Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial” in Archives of General Psychiatry has received substantial media attention and professional attention. The study has been selected as one of “The Most Important Studies of 2010” (Medscape Psychiatry) and as a trial “most likely to change clinical practice” (DynaMed). To date, the study has been cited >300 times reflecting its landmark status for early intervention. Dr Amminger’s research work has been awarded with seven national awards (Austria) and two international awards. He is supervising PhD and Honours students at Medical University Vienna and at the University of Melbourne. He is Associate Editor of the journal Early Intervention in Psychiatry.
T: +61 3 9342 2800
Optymise Research Themes
- Phase II behavioural and medical therapy clinical trials
- Clinical and population-based longitudinal and family studies